2020

1. A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study

   Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 420-428

2. Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)

   Breast, Vol. 54, pp. 286-292

3. Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study)

   Breast Cancer Research and Treatment, Vol. 184, Núm. 2, pp. 469-479